MAPT and Alzheimer disease: Photocatalyst 4 showed high photo-oxygenation activity for both Aβ and tau (Ozawa et al., 2021), indicating the high potential of photo-oxygenation as a therapeutic strategy for AD, by targeting both Aβ and tau.